SR9238 is liver selective LXR inverse agonist with high potency for both LXRα and LXRβ with an IC50 of 214 nM for LXRα and 43 nM for LXRβ. Metabolic syndrome is often accompanied by liver problems, such as fatty liver (nonalcoholic hepatosteatosis), associated with increased lipogenesis. Liver X receptors α and β (LXRα and LXRβ) are known to induce lipogenesis by increasing transcription of lipogenic enzyme genes, so it was hoped LXR antagonists might be of use in fatty liver. In a mouse model of nonalcoholic hepatosteatosis, SR9238 reduced the expression of lipogenic genes, and suppressed hepatic lipogenesis, inflammation and hepatic lipid accumulation. It was also effective in reduction of hepatic fibrosis in another study. Additionally in diet induced obese mice, SR9238 suppressed plasma cholesterol levels.
SR9238 is liver selective LXR inverse agonist with high potency for both LXRα and LXRβ.
Cell and tissue research, 378(1), 81-96 (2019-04-24)
Self-renewal of macrophages is important for the healthy development and replenishment of tissue-resident macrophage pools. How this mechanism is controlled by endocrine signals is still largely unexplored. Here, we show that the endocrine disruptor bisphenol A (BPA) increases macrophage self-renewal.
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
